Neonatal hyperbilirubinemia. Neonatal jaundice from breast milk inhibitor
Conditions
Interventions
Intervention 1: The study group received Saccharomyces boulardii (Reflor®, Biocodex, France, 50 mg/kg per dose twice daily) during phototherapy. Intervention 2: The control group received placebo (dis
1 cc per dose twice daily) during phototherapy.
Treatment - Drugs
Placebo
The study group received Saccharomyces boulardii (Reflor®, Biocodex, France, 50 mg/kg per dose twice daily) during phototherapy.
Sponsors
Health Ministry Drug and Pharmacy General Management
Eligibility
Sex/Gender
All
Age
No minimum to 1 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1. Late preterm (34, not completed week – 36, completed week) gestational weeks ) and term (= 37 gestational weeks) neonates 2. Newborns who need phototherapy for neonatal hyperbilirubinemia 3. Newborns who were 0-1 month old. Exclusion criteria: 1. Newborns who have congenital anomalies 2. Newborns who need intense phototherapy 3. Direct coombs positive ABO/Rh incompatability 4. Neonates who have sepsis/pneumonia during phototherapy 5. Neonates with hypothyroidism 6. Neonates who have gastrointestinal obstruction 7. Neonates with asphyxia 8. Contraindication of peroral feeding
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Phototherapy duration. Timepoint: Starts at the same time with the intervention. Method of measurement: Patients' medical records.;Maximum bilirubinemia level. Timepoint: Starts at the same time with the intervention. Method of measurement: Patients' laboratory records. | — |
Countries
Turkey
Contacts
Public ContactFahri Ovali
Zeynep Kamil Maternity and Children Education and Training Hospital
Outcome results
None listed